GLPwatch
Semaglutide as a possible therapy for healthy aging: Targeting the hallmarks of aging.
Ageing Res Rev · 2024
Last updated 2026-05-28The study explores whether semaglutide, a drug already used for diabetes and weight loss, could help slow aging by targeting key aging-related processes like inflammation, oxidative stress, and stem cell depletion. The research suggests semaglutide may influence these processes, but does not provide specific results or outcomes.
AI summary of the abstract below.
| Journal | Ageing Res Rev, 2024 |
|---|---|
| Citations | 5 |
| Relative citation ratio | 0.90 |
| NIH percentile | 47 |
| Molecules | semaglutide |
| Conditions studied | Alzheimers, Cardiovascular Risk Reduction, Chronic Kidney Disease, Depression, Obesity, Type 2 Diabetes |
Abstract
With an aging population, the investigation of therapies that promote healthy aging becomes increasingly urgent. Here we discuss how Semaglutide can be a potential therapy to contribute to this goal by targeting key hallmarks of aging, such as inflammation, oxidative stress and stem cell exhaustion.
Verbatim abstract via PubMed 39547367 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.